Total raised
$16.9M
Last: Convertible Debt 2024-05
Stage
Series B
Founded
2012
Headcount
17
HQ
Modi'in-Maccabim-Re'ut
Sector
Health Tech & Life Sciences
About
FEMSelect is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. The EnPlace procedure takes approximately 30 minutes. Its patented delivery system enables precise guidance, insertion, and deployment of the anchor unit, which is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization. EnPlace is FDA cleared and CE marked. The device is a combination of a Nitinol-based anchor, surgical sutures, and an innovative attachment method, and the surgery is conducted with no deep dissection or mesh. EnPlace has been tested in a human trial in Israel and is protected by global and U.S. patents.
Funding history · 6 rounds · $16.9M total
2024-05
Convertible Debt
$540K
2022-10
Series B
$9.0M
2020-12
Convertible Debt
$2.7M
2019-12
Convertible Debt
$900K
2017-05
Series A
$3.0M
2012-12
Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
ConsumersDemographics & FamilyWomenHealthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 PatentsVerified
Tags
medical-devicesgynecologyminimally-invasivemedical-technologieswomen-healthdoctorssurgeonshospitalstreatmentsfemtech